相关实验视频

Updated: Jun 30, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

BTN1A1是一种新的免疫检查点,与PD-L1相互排斥

Young-Seung Kim¹, Seung-Hoon Lee¹, Andrew H Park¹

¹STCube Pharmaceuticals, Inc, Gaithersburg, Maryland, USA.

Journal for immunotherapy of cancer

|March 14, 2024

概括

布蒂罗菲林1A1 (BTN1A1) 作为一种新的免疫检查点,抑制T细胞活性和瘤清除. 用抗体向BTN1A1显示出治疗PD-1/PD-L1疗法耐药癌症的希望.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

编程细胞死亡蛋白1 (PD-1) /编程细胞死亡连接体1 (PD-L1) 阻断是一种癌症治疗方法,但其疗效有限.
对于那些对当前疗法没有反应的患者,需要新的免疫检查点.
布蒂罗菲林1A1 (BTN1A1) 具有潜在的免疫调节活性,需要进一步研究.

研究的目的:

系统地评估Butyrophilin 1A1 (BTN1A1) 作为一个免疫检查点.
描述BTN1A1免疫调节活动的机制.
评估BTN1A1作为癌症免疫治疗的潜在治疗标.

主要方法:

在瘤组织中分析了BTN1A1表达.
在BTN1A1.1存在的情况下,T细胞激活和瘤清除被评估.
研究了BTN1A1和PD-L1之间的关系.
一种BTN1A1特异性抗体被开发出来,并在小鼠模型中进行了测试.

主要成果:

证实BTN1A1可以抑制T细胞激活在体外和体内.
在各种固体瘤中发现了高BTN1A1表达.
BTN1A1表达与PD-L1表达是相互排斥的.
在小鼠中,抗体介导的BTN1A1阻塞抑制了瘤生长和增加了免疫细胞透.

结论:

布蒂罗菲林1A1 (BTN1A1) 是一个经过验证的免疫检查点.
BTN1A1代表了抗PD-1/PD-L1耐火性或耐药性癌症的可行的免疫治疗标.
针对BTN1A1可能会改善各种癌症患者的生存结果.

关键词:

抗体的特异性抗体的特异性药物评估,临床前临床免疫检查点抑制剂免疫检查点抑制剂免疫逃生是免疫逃生的一种方式.免疫治疗是一种免疫疗法.

更多相关视频

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...